BillionToOne
IPO on NASDAQ: BLLN
Genetic testing tool for prenatal screening and cancer therapy selection via blood samples
Revenue
$153.00M
2024
Valuation
$1.00B
2024
Funding
$407.89M
2024
Growth Rate (y/y)
112.5%
2024
Details
Headquarters
Menlo Park, United States
CEO
Oguzhan Atay
Website
Milestones
FOUNDING YEAR
2016
IPO
November 2025
Listed In
News
The latest coverage and announcements from BillionToOne.